That discovery launched investigations into whether a vaccine with live, attenuated horsepox could confer immunity without ...

Presentation details for Appili are as follows: Poster Title: Toward the clinical development of ATI-1701, a genetically defined live attenuated tularemia vaccine Date: October 17 th, 2024 ATI ...

New data show tolerability and no evidence of spreading to blood or tissues even at high doses of Tonix’s attenuated live-virus, minimally ...

ATI-1701 is a novel, live-attenuated vaccine for F. tularensis, which causes tularemia, a Category A pathogen which can be aerosolized and is over 1,000 times more infectious than anthrax.

To request a meeting with Appili, please contact [email protected]. ATI-1701 is a novel, live-attenuated vaccine for F. tularensis, which causes tularemia, a Category A pathogen which can be ...

The poster presentation will provide an update on ATI-1701, Appili’s potential first-in-class vaccine candidate for the prevention of tularemia caused by F. tularensis and will summarize the ...

Detailed price information for Appili Therapeutics Inc (APLI-T) from The Globe and Mail including charting and trades.

HALIFAX, Nova Scotia, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical ...